You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰凌醫藥(01011.HK)獲授Orticumab於大中華等地商業化獨家永久許可
阿思達克 06-22 08:18
泰凌醫藥(01011.HK)公佈,公司附屬從Abcentra LLC獲得於中國內地、香港、澳門、臺灣、新加坡、馬來西亞及泰國等地區將單克隆抗體(Orticumab)商業化的獨家永久許可。 該技術目前處於臨牀試驗II期,由許可方開發,用於治療動脈粥樣硬化性心血管疾病、牛皮癬、類風溼性關節炎、系統性紅斑狼瘡及鈣化性主動脈瓣疾病等五種疾病。Orticumab將利用公司現有的藥物銷售及分銷網絡及經驗在地區內實現商業化。 作爲許可先決條件之一此,公司將委聘顧問提供顧問服務。作顧問服務的代價,待所有先決條件獲達成後,公司將根據特別授權按發行價每股代價股份0.2元向顧問配發及發行約4.73億股代價股份,發行價較公司股份在聯交所前一個交易日收市價折讓約6.1%。 公司又宣佈,正與潛在買方就訂立出售協議進行磋商的後期階段,公司間接全資附屬公司蘇州第壹擬出售若幹有形及無形資產。商業化權利的許可、潛在出售及框架協議如作實,將構成集團業務重組。董事認爲,有關重組將顯着改善 集團的流動資金狀況。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account